Summary
Introduction
MannKind, a development-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic products for metabolical disorder and cancer. Technosphere Insulin (TI) System is the company's lead product candidate in Phase III development for treatment of type 1 and type 2 diabetes. The company is studying MKC1106 in Phase I trials for potential treatment of solid tumors.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's insulin inhaler, Technosphere Insulin System is being studied in Phase III pivotal trails for diabetes in the US, Europe and Latin America. MKC1106, the company's potential cancer drug, is in Phase I trials for the treatment of solid tumors. MannKind recognized revenues of $0.1 million under a license agreement in 2006. The company did not record revenues between 2002 and 2005. The company is expected to generate revenues of $283.9 million during 2006-2010, as its lead product candidate TI System will contribute majority of revenue growth during the period in analysis.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
